Tesamorelin is a full 44-amino-acid GHRH analog with an N-terminal hexenoyl modification conferring DPP-4 resistance. Phase III data in HIV-associated lipodystrophy demonstrated −27.8 cm² VAT reduction vs. +5.1 cm² in placebo. Research models characterize GHRH-R → pulsatile GH → hepatic IGF-1 → visceral lipolysis pathway. Independent research compilation for scientific and educational reference only.

Thymosin Alpha-1 (Tα1) is a 28-amino-acid thymic peptide studied for TLR-9 agonism on plasmacytoid dendritic cells. Preclinical models document Th1 cytokine polarization (↑IL-12, IFN-γ; ↓IL-10), NK cell activation, and IDO pathway modulation. Independent research compilation for scientific and educational reference only.

SLU-PP-332 is a synthetic pan-ERR agonist studied as an exercise mimetic in preclinical models. Rodent data shows 70% increase in treadmill endurance, 10× less fat gain in obese models, and cardiac function improvement in heart failure models — all ERRα-dependent. Thin but active literature; 6-8 primary papers as of 2026. Independent research compilation for scientific and educational reference only.

SS-31 (Elamipretide) is a Szeto-Schiller tetrapeptide that selectively binds cardiolipin at the inner mitochondrial membrane (KD = 1.87 μM). Preclinical models document cristae preservation, ETC supercomplex stabilization, and restored ATP production in aging and ischemia models. Independent research compilation for scientific and educational reference only.

PT-141 (Bremelanotide) is a cyclic melanocortin receptor agonist studied for MC3R/MC4R activation in hypothalamic circuits. Preclinical models document dose-dependent behavioral endpoints via dopaminergic and oxytocin pathways — distinct from PDE5 inhibitor mechanisms. Independent research compilation for scientific and educational reference only.